Monograph
R03AC03 - Terbutaline |
Not porphyrinogenic |
NP |
Rationale
Probably non-CYP metabolism. One reference: authorised. Significant clinical experience of non-porphyrinogenicity.
Chemical description
Adrenergic used in asthma administered in inhalation aerosol (5 mg 4 times/day) in asthma. Metabolized by sulfatation and excreted in urine in conjugated form. No clinical data pointing to CYP-interaction. French list: authorized. C.Andersson, patient reports: tolerated (n=11). Used in porphyria ward (Swden).
IPNet drug reports
Uneventful use reported in 20 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Iceland
Finland© NAPOS 2024